Pilot Study of Cefditoren Pivoxil in COVID-19 Patients With Mild to Moderate Pneumonia
Status:
Completed
Trial end date:
2021-08-15
Target enrollment:
Participant gender:
Summary
The global pandemic of novel coronavirus disease 2019 (COVID-19) began in Wuhan, China, in
December 2019, and has since spread worldwide. The disease is mild in 85% of cases but the
remaining 15% requires hospitalization and/or intensive care.
Recent publications show that a significant number of COVID-19 patients are co-infected with
one or more pathogens. Most co-infections occurred within 1-4 days of onset of COVID-19
disease and a considerable number of patients arrive to the Emergency rooms with
mild-moderate respiratory symptoms compatible with pneumonia of presumed bacterial origin and
not severe enough for requiring hospitalization. It therefore seems reasonable to adopt
therapeutic strategies for these patients that are effective and easy to follow in the
outpatient setting.
Cefditoren (CDN) is a third-generation cephalosporin for oral administration. CDN has a broad
spectrum of activity and is particularly active against the bacterial pathogens involved in
community respiratory tract infections. Besides that, the use of CDN has been associated with
a marked decrease in circulating levels of IL-6 and other pro-inflammatory cytokines and
mediators of epithelial damage. The aim of this study is to demonstrate that CDN improves
clinical condition in patients with mild-moderate COVID-19 and symptoms of bacterial
pneumonia.